Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 3/20 | 0.52 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.50 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.50 |
| ▸ | RPS17 | P08708 | 1/20 | 0.50 |
| ▸ | RPSA | P08865 | 1/20 | 0.50 |
| ▸ | RPS2 | P15880 | 1/20 | 0.50 |
| ▸ | RPL35A | P18077 | 1/20 | 0.50 |
| ▸ | RPL7 | P18124 | 1/20 | 0.50 |
| ▸ | RPL17 | P18621 | 1/20 | 0.50 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.50 |
| ▸ | RPS3 | P23396 | 1/20 | 0.50 |
| ▸ | RPS12 | P25398 | 1/20 | 0.50 |
| ▸ | RPL13 | P26373 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725933 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| SCHEMBL251728 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| SCHEMBL29167395 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| SCHEMBL12172739 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| SCHEMBL14183583 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| SCHEMBL4247918 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| SCHEMBL4406664 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| SCHEMBL3912679 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| Hydrochloric Acid SCHEMBL11703545 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 | |
| Hydrochloric Acid SCHEMBL10626955 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CYP3A4LMNASMN1; SMN2MARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133248-A1 | DIASTEREOMERIC AMINOALCOHOL AND AMINOETHER SALTS OF 2-[(4R,S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-YL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL]-3,4-DIHYDROQUINAZOLIN-4-YL]ACETIC ACID AND THEIR USE FOR ENANTIOMERIC SEPARATION | AIC246 AG & CO. KG (DE) | 2025-06-26 | — | — | WO | claimed |
| CN-111099993-B | Preparation method of (S) -2-hydroxy-3-methoxy-3, 3-diphenyl propionic acid | 常州恒邦药业有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-110819000-B | Waterproof ventilated membrane of polypropylene | 温州大学 | 2022-02-15 | — | — | CN | claimed |
| CN-107686488-B | Synthesis method of biotin intermediate | 浙江医药股份有限公司新昌制药厂 | 2020-04-28 | — | — | CN | claimed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | claimed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | claimed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | claimed |
| US-4014895-A | Method for synthesis of optically active thiolactones | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-03-29 | — | — | US | claimed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250325644-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | ELICIO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | MERCK SERONO SA (CH) | 2003-11-13 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
| US-6121460-A | Process for the preparation of an optically active indoline-2-carboxylic acid or derivative thereof | DSM N.V. (NL) | 2000-09-19 | — | — | US | disclosed |
| US-4014895-A | Method for synthesis of optically active thiolactones | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, CNR1, PRLHR | ALDH1A1 3384/4885CYP3A4 1961/4885LMNA 4054/4885 |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | SOST, PTMS, FGF23 | ALDH1A1 3724/4885CYP3A4 2752/4885LMNA 1125/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | ALDH1A1 3922/4885CYP3A4 1489/4885LMNA 2888/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | ALDH1A1 2964/4885CYP3A4 1365/4885LMNA 1747/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | ALDH1A1 733/4885CYP3A4 2895/4885LMNA 2073/4885 |
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | ALDH1A1 350/4885CYP3A4 86/4885LMNA 3541/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | ALDH1A1 3249/4885CYP3A4 1024/4885LMNA 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.